Licensed provider review·support@lumoramd.com·Log in
← Medications
MedicationWeight Management & Metabolic Health

Tirzepatide + Glycine.

Compounded tirzepatide formulated with glycine for stability and tolerability.

5 / 10 / 15 / 20 / 25 / 30 mg tirzepatide with 0.5 mg glycine per mL · subcutaneous injectable

Pricing is shown after your free assessment, before you commit.

Start provider review →

Free to start. No card required.

Is this for you?

This is for you if

  • Patients on tirzepatide who do not tolerate B12 or prefer to avoid it
  • Patients sensitive to cobalt or cobalamin
  • Patients pursuing precise physician-guided titration across six concentration tiers

This isn't for you if

All safety information for tirzepatide applies — see the Tirzepatide product page.

What it is

Tirzepatide + Glycine

This formulation combines compounded tirzepatide with glycine — used in compounded formulations for solution stability and pH buffering. It is the standard alternative for patients who don't tolerate or don't want B12 in their weekly injection.

How it works

Mechanism and fit.

Tirzepatide activates GIP and GLP-1 receptors exactly as the standalone formulation does. Glycine supports formulation stability and offers modest independent research interest in metabolic and sleep support.

When it may fit

Who this is typically for.

  • Patients on tirzepatide who do not tolerate B12 or prefer to avoid it
  • Patients sensitive to cobalt or cobalamin
  • Patients pursuing precise physician-guided titration across six concentration tiers
Tirzepatide + Glycine - common questions

What patients
most often ask.

Will I lose less weight on the glycine version?+

No. The tirzepatide content is identical to the B12 formulation. The cofactor differs, not the active medication.

When it may fit

Who this is typically for.

These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.

  • <ul><li>Patients on tirzepatide who do not tolerate B12 or prefer to avoid it</li><li>Patients sensitive to cobalt or cobalamin</li><li>Patients pursuing precise physician-guided titration across six concentration tiers</li></ul>
Provider plan

How this option
is evaluated.

The plan is provider-determined after reviewing your assessment and safety factors.

  • DosingWeekly subcutaneous injection, titrated by your provider.
  • Typical durationLong-term, individualized based on response and labs.
  • Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
How care works
  • A licensed provider reviews your assessment before any treatment is recommended.
  • You see full pricing - visit fees, medication, labs, follow-up - before you commit.
  • Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
  • Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.

Start with
provider review.

If you are considering Tirzepatide + Glycine, the first step is a free assessment. A provider determines whether it fits your goals and medical history.

Start provider review →

A provider determines whether treatment is clinically appropriate.

Important information
Lumora may prescribe FDA-approved or compounded medications when clinically appropriate. Compounded medications are not approved by the FDA and are dispensed by a licensed pharmacy under the supervision of a licensed provider.